机构：[1]Yu-Yue Pathology Scientific Research Center, Chongqing 400039, China.[2]Jinfeng Laboratory, Chongqing 401329, China.[3]Department of Oncology & Cancer Institute, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.四川省人民医院[4]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610042, China.四川省肿瘤医院[5]Cancer Center, Medical Research Institute, Southwest University, Chongqing 400716, China.[6]Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.四川省人民医院[7]Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine & Guangxi Engineering Center in Biomedical Material for Tissue and Organ Regeneration & Key Laboratory of Longevity and Aging-related Diseases of Chinese Ministry of Education, Guangxi Medical University, Nanning 530021, China.[8]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Par6 alpha encoded by PARD6A is a member of the PAR6 family and is reported to promote cancer initiation and progression. PARD6A is frequently upregulated in different types of cancers, but its regulatory role in lung cancer progression is yet to be established. In this study, we analyzed the PARD6A expression in biopsies from lung adenocarcinoma (LUAD) patients, and the survival probability using LUAD tissue microarray (TMA) and online datasets from TCGA and GEO. We conducted in vitro and in vivo assays to assess the role of PARD6A in regulating lung cancer progression, including proliferation, wound healing, transwell, RNA-seq, and subcutaneous tumor mice models. Our findings revealed that PARD6A is highly expressed in cancer tissues from LUAD patients and is associated with poor prognosis in LUAD patients. In vitro assays showed that PARD6A promoted cell proliferation, migration, and invasion. The transcriptome sequencing identified Serpina3 as one of the key downstream molecules of PARD6A. Ectopic expression of Serpina3 rescued impaired proliferation, migration, and invasion in PARD6A-knocking down H1299 cells, whereas silencing Serpina3 impeded enhanced proliferation, migration, and invasion in PARD6A-overexpressing H1975 cells. Our findings suggest that PARD6A promotes lung cancer progression by inducing Serpina3, which may be a promising therapeutic target.
基金：
National Natural Science Foundation of China (National Science Foundation of China) [2023YFC3402100]; National Key Research and Development Program of China [92259102]; National Natural Science Foundation of China
基金编号：2023YFC340210092259102
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区医学
小类|2 区生物工程与应用微生物3 区遗传学3 区医学：研究与实验4 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|2 区生物工程与应用微生物3 区遗传学3 区医学：研究与实验4 区肿瘤学
JCR分区：
出版当年[2023]版：
Q1BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ1GENETICS & HEREDITYQ1MEDICINE, RESEARCH & EXPERIMENTALQ1ONCOLOGY
最新[2023]版：
Q1BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ1GENETICS & HEREDITYQ1MEDICINE, RESEARCH & EXPERIMENTALQ1ONCOLOGY
第一作者机构：[1]Yu-Yue Pathology Scientific Research Center, Chongqing 400039, China.[2]Jinfeng Laboratory, Chongqing 401329, China.[3]Department of Oncology & Cancer Institute, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
共同第一作者：
通讯作者：
通讯机构：[1]Yu-Yue Pathology Scientific Research Center, Chongqing 400039, China.[2]Jinfeng Laboratory, Chongqing 401329, China.[3]Department of Oncology & Cancer Institute, Sichuan Academy of Medical Science and Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.[8]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
推荐引用方式(GB/T 7714)：
Hu Lanlin,Liu Mingxin,Tang Bo,et al.PRAD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3[J].CANCER GENE THERAPY.2024,doi:10.1038/s41417-024-00829-w.
APA：
Hu, Lanlin,Liu, Mingxin,Tang, Bo,Li, Xurui,Xu, Huasheng...&Xu, Chuan.(2024).PRAD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3.CANCER GENE THERAPY,,
MLA：
Hu, Lanlin,et al."PRAD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3".CANCER GENE THERAPY .(2024)
